Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation

Transfusion

Volumn 56, Issue 5, 2016, Pages 1096-1100

  Bramanti, Stefania ^a   Nocco, Angela ^b   Mauro, Elisa ^c   Milone, Giuseppe ^c   Morabito, Lucio ^a   Sarina, Barbara ^a   Crocchiolo, Roberto ^a   Timofeeva, Inna ^a   Capizzuto, Rossana ^a   Carlo Stella, Carmelo ^a   Santoro, Armando ^a   Castagna, Luca ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Ospedale Ferrarotto   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B41 ANTIGEN; IMMUNOGLOBULIN; MEROPENEM; MYCOPHENOLATE MOFETIL; PIPERACILLIN PLUS TAZOBACTAM; STEROID; TACROLIMUS; THIOTEPA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHIMERA; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; DESENSITIZATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA TYPING; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; PHOTOTHERAPY; PLASMAPHERESIS; PYREXIA IDIOPATHICA; RECURRENT FEVER; STEROID THERAPY; T LYMPHOCYTE;

EID: 84962295837     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13523     Document Type: Article

References (20)

1. Appelbaum FR., Alternative donor transplantation for adults with acute leukemia. Best Pract Res Clin Haematol 2014; 27: 272-7.
2. Ruggeri A, Ciceri F, Glukman E, et al., Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: umbilical cord blood or haploidentical donors? Best Pract Clin Res Haematol 2010; 23: 207-16.
3. Mattsson J, Ringdén O, Storb R., Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 165-70.
4. Pei J, Akatsuka C, Anasetti C, et al., Generation of HLA-C-specific cytotoxic T cells in association with marrow graft rejection: analysis of alloimmunity by T-cell cloning and testing of T-cell receptor rearrangements. Biol Blood Marrow Transplant 2001; 7: 378-83.
5. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al., Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies, against donor cells. Lancet 1966; 2: 662-5.
6. Taylor PA, Ehrhardt MJ, Roforth MM, et al., Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 3: 1307-15.
7. Barge AJ, Johnson G, Witherspoon R, et al., Antibody mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989; 74: 477-88.
8. Kekre N, Antin JH., Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014; 124: 334-43.
9. Colson YL, Schuchert MJ, Ildstad ST., The abrogation of allosensitization following the induction of mixed allogenic chimerism. J Immunol 2000; 65: 637-44.
10. Castagna L, Crocchiolo R, Furst S, et al., Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724-9.
11. Gladstone DE, Zachary AA, Fuchs EJ, et al., Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013; 19: 647-52.
12. Luznik L, O'Donnell PV, Symons HJ, et al., HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 6: 641-50.
13. Yoshihara S, Maruya E, Taniguchi K, et al., Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012; 4: 508-15.
14. Ciurea SO, de Lima M, Cano P, et al., High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 8: 1019-24.
15. Takanashi M, Atsuta Y, Fujiwara K, et al., The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 15: 2839-46.
16. Cutler C, Kim HT, Sun L, et al., Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 25: 6691-7.
17. Spellman S, Bray R, Rosen-Bronson S, et al., The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 13: 2704-8.
18. Bashey A, Zhang X, Sizemore CA, et al., T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 10: 1310-6.
19. Montgomery RA, Lonze BE, King KE, et al., Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-26.
20. Narimatsu H, Wake A, Miura Y, et al., Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005; 6: 555-6.